Korea United Pharm
유나이티드제약 · 033270
Health Care Pharmaceuticals · KOSPI
Market cap US$208.7M (₩288B)
Overview
Korea United Pharm makes prescription medicines, including drugs for circulation, digestion, and other conditions, that are supplied to patients through hospitals and pharmacies in Korea and exported to dozens of countries worldwide.
Listed on KOSPI, Korea's main stock exchange, the company focuses on 'improved new drugs' (reformulated or enhanced versions of existing medicines that offer better delivery or efficacy). Its single most defining structural fact is that it consistently reinvests a high share of revenue back into research and development, and has launched nearly two dozen improved or newly formulated drug products to date.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$202.1M
- FY2024US$209.2M
- FY2025US$209.2M
Operating profit
- FY2023US$39.8M
- FY2024US$40.8M
- FY2025US$35.9M
Net income
- FY2023US$35M
- FY2024US$23.5M
- FY2025US$27.8M
Key ratios (FY2025)
Why it matters
The South Korean government has formally designated the company as an 'innovative pharmaceutical enterprise,' a national recognition that reflects its R&D-focused business model.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?